Back to basics: Luring industry back into neuroscience

Nature Neuroscience

Volumn 19, Issue 11, 2016, Pages 1383-1384

  Hyman, Steven E ^a,b  

^a Harvard University   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS;

APPROPRIATE TECHNOLOGY; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; GENETIC BACKGROUND; GENETIC CONSERVATION; HUMAN; HUMAN GENETICS; IN VIVO STUDY; LETTER; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ECONOMICS; GENETICS; TRENDS;

ANIMALS; BRAIN DISEASES; DRUG INDUSTRY; HUMANS; NEUROSCIENCES;

EID: 84994143502     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.4429     Document Type: Letter

References (9)

1. Bunnage, M.E. Nat. Chem. Biol. 7, 335-339 (2011).
2. Pankevich, D.E., Altevogt, B.M., Dunlop, J., Gage, F.H. & Hyman, S.E. Neuron 84, 546-553 (2014).
3. Hyman, S.E. Sci. Transl. Med. 4, 155cm11 (2012).
4. Institute of Medicine. Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. (National Academies Press, Washington, DC, 2013).
5. Institute of Medicine. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. (National Academies Press, Washington, DC, 2013).
6. Nestler, E.J. & Hyman, S.E. Nat. Neurosci. 13, 1161-1169 (2010).
7. Sittig, L.J. et al. Neuron 91, 1253-1259 (2016).
8. Sullivan, P.F., Daly, M.J. & O'Donovan, M. Nat. Rev. Genet. 13, 537-551 (2012).
9. Doan, R.N., Bae, B.-I., Cubelos, B., Chang, C. et al. Mutations in human accelerated regions disrupt cognition and social behavior. Cell http://dx.doi. org/10.1016/j.cell.2016.08.071 (2016)